[7-[6-[4-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoylamino]hexylcarbamoyloxy]-4-[3-[6-[4-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoylamino]hexylcarbamoyloxy]propyl]-4-methylheptyl] N-[4-[4-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoylamino]butyl]carbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [7-[6-[4-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoylamino]hexylcarbamoyloxy]-4-[3-[6-[4-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoylamino]hexylcarbamoyloxy]propyl]-4-methylheptyl] N-[4-[4-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanoylamino]butyl]carbamate
• 化学式: C₆₀H₁₁₃N₉O₂₄
• 分子量: 1344.6
• InChiKey: VUCIZCQBCRJJBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  93
• 可旋转键数：
  52
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  518
• 氢给体数：
  18
• 氢受体数：
  27

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20130178512A1

  公开（公告）日：2013-07-11

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.
• ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20140179768A1

  公开（公告）日：2014-06-26

  The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
• SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160257954A1

  公开（公告）日：2016-09-08

  The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
• US8828956B2
  申请人：——

  公开号：US8828956B2

  公开（公告）日：2014-09-09
• US9322018B2
  申请人：——

  公开号：US9322018B2

  公开（公告）日：2016-04-26